Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: Further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP)
To access this article, please choose from the options below
Funded by the Medical Research Council of Canada (grant MT-13288). The US centers were supported in part by NICHD (grants U10 HD21364, U10 HD27851, U10 HD21373, U10 HD27881; M01 RR 00997, U10 HD27880; M01 RR 00070, U10 HD21385, U10 HD27904, and U10 HD34216). The INDOCID PDA was donated by Merck Frosst.
PII: S0022-3476(06)00074-6
doi:10.1016/j.jpeds.2006.01.047
© 2006 Elsevier Inc. All rights reserved.
Refers to article:
- Treatment to prevent patency of the ductus arteriosus: Beneficial or harmful?
